Freenome says updated SimpleScreen CRC blood test lifts lesion sensitivity to 18.2% in validation study
ABT•Freenome said an updated SimpleScreen CRC blood test raised sensitivity for advanced precancerous colorectal lesions to 18.2% in a validation study, while colorectal cancer detection held steady versus the first-generation test. The results are scheduled for an Oct. 14 presentation at ACG 2026.
1. Validation results
Freenome announced validation results for an updated SimpleScreen CRC blood test, reporting 18.2% sensitivity for advanced precancerous colorectal lesions. Colorectal cancer detection held steady versus the first-generation test, which received FDA clearance in July 2026.
2. Presentation and launch
The new dataset is scheduled for an oral presentation on Oct. 14 in Nashville at ACG 2026. Abbott Cancer Diagnostics launched the first-generation test commercially in the United States in late September.
